Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Johnson & Johnson reported that once-daily
“Mania is among the most dangerous and worrisome phases of bipolar disorder,” Michael E. Thase, MD, professor of psychiatry at the University of Pennsylvania and a consultant and adviser to Johnson & Johnson, said in a press release.1 “These results are encouraging because CAPLYTA® not only significantly improved the symptoms of mania, but did so as early as Day 3, with benefits sustained through Week 3, supporting its potential to meaningfully advance how we treat acute mania in bipolar I disorder."
Study 451 was a randomized, double-blind trial comparing lumateperone with placebo in adults experiencing manic episodes, with or without mixed features, associated with bipolar I disorder. Participants received lumateperone 42 mg or placebo once daily for 3 weeks.1,2
At week 3, lumateperone produced a 4.8-point greater reduction from baseline in Young Mania Rating Scale (YMRS) total score than placebo, meeting the primary end point. The reported effect size was −0.69 (P < .0001). A statistically significant between-group difference was observed by day 3.1
Overall illness severity also improved. On the Clinical Global Impression–Severity scale, the least-squares mean difference favoring lumateperone was −0.5 at week 3 (P < .0001). A YMRS response, defined as a reduction of at least 50% from baseline, occurred in 45.8% of lumateperone-treated participants and 20.9% of placebo recipients (P < .0001).1,2
The most frequently reported treatment-related adverse events occurring in at least 5% of the lumateperone group and at least twice the placebo rate were dry mouth (7.9% vs 3.4%) and nausea (7.9% vs 2.3%). The company characterized discontinuation rates as low but did not report numerical rates or a complete adverse-event table.
Bipolar disorder is a lifelong, recurrent illness characterized by episodes of depression and mania; approximately 37 million people are affected worldwide.3 Mania can include elevated or irritable mood, decreased need for sleep, grandiosity, distractibility, and risk-taking behavior. Episodes may intensify rapidly and require hospitalization. A recent review emphasized that heterogeneous presentations, frequent comorbidity, and treatment tolerability remain important challenges in bipolar disorder management.4
Lumateperone is an oral atypical antipsychotic. Its precise mechanism is unknown, but its clinical effects may involve serotonin 5-HT2A receptor antagonism and dopamine D2 receptor partial agonism. In the US, it is approved for schizophrenia; bipolar depression as monotherapy or adjunctive therapy with lithium or valproate; and major depressive disorder as adjunctive therapy with an antidepressant.1
The drug carries class-related risks that include increased mortality in older adults with dementia-related psychosis, neuroleptic malignant syndrome, tardive dyskinesia, metabolic abnormalities, leukopenia, orthostatic hypotension, falls, seizures, and somnolence. These established warnings remain relevant even though no new safety signal was highlighted in Study 451.
The findings support further regulatory evaluation but do not establish comparative effectiveness against an active antimanic treatment. The short duration also limits assessment of maintenance efficacy, relapse prevention, uncommon adverse events, and longer-term metabolic or neurologic effects. Full peer-reviewed results, including enrollment, subgroup, discontinuation, and comprehensive safety data, are needed. Johnson & Johnson said a second pivotal phase 3 trial, Study 452, has been completed and is undergoing analysis.1
